Expanded Access to MGAWN1 in Subjects With: Suspected West Nile Neuroinvasive Disease; Suspected West Nile Virus Infection and a Compromised Immune System; or Substantial Accidental Exposure to West Nile Virus.
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 05 Jul 2011
At a glance
- Drugs MGAWN1 (Primary)
- Indications West Nile virus infections
- Focus Therapeutic Use
- 05 Jul 2011 Status changed from suspended to active, no longer recruiting as reported by ClinicalTrials.gov.
- 01 Nov 2010 Status changed from recruiting to suspended, according to ClinicalTrials.gov.
- 29 Sep 2010 New trial record